Thrombosis research最新文献

{"title":"All-cause mortality after major gastrointestinal bleeding among patients receiving direct oral anticoagulants: a systematic review and meta-analysis","authors":"Nicholas L.J. Chornenki ,&nbsp;Roupen Odabashian ,&nbsp;Marc Carrier ,&nbsp;Faizan Khan ,&nbsp;Jenneke Lenteejens ,&nbsp;Fabian Stucki ,&nbsp;Tzu-Fei Wang ,&nbsp;Tobias Tritschler ,&nbsp;Deborah M. Siegal","doi":"10.1016/j.thromres.2025.109352","DOIUrl":"10.1016/j.thromres.2025.109352","url":null,"abstract":"<div><h3>Background</h3><div>Although gastrointestinal (GI) bleeding represents the single most frequent site of anticoagulant-related major bleeding, outcomes after major GI bleeding including mortality are not well characterized and severity may be underappreciated. We aimed to determine 30-day all-cause mortality in adults with major GI bleeding on a direct oral anticoagulant (DOAC).</div></div><div><h3>Methods</h3><div>We searched MEDLINE, EMBASE, and Cochrane CENTRAL from inception to May 9, 2024 for randomized controlled trials and cohort studies that reported 30-day all-cause mortality after major GI bleeding in adults treated with a DOAC for venous thromboembolism or atrial fibrillation. Risk of bias was assessed using a modified QUIPS tool for prognostic studies. 30-day all-cause mortality was calculated using the random-effects inverse-variance method.</div></div><div><h3>Results</h3><div>We included 20 studies comprising 3987 DOAC-treated patients with major GI bleeds. The pooled estimate of 30-day all-cause mortality was 8.4 % (95 % confidence interval [CI], 4.9–12.5; I² = 83 %). In subgroup analyses, 30-day all-cause mortality was 10.3 % (95 % CI, 6.5–14.7; I² = 24 %) in prospective studies (9 studies, 675 major GI bleeds), 7.3 % (95 % CI, 2.2–14.4; I² = 90 %) in retrospective studies (11 studies, 3312 major GI bleeds), 12.9 % (95 % CI, 6.3–21.1; I² = 44 %) in considered at high risk of bias (9 studies, 387 major GI bleeds), and 6.1 % (95 % CI, 2.9–10.1; I² = 89 %) in those at low risk of bias (10 studies, 3562 major GI bleeds).</div></div><div><h3>Conclusion</h3><div>DOAC-related major GI bleeding appears to be associated with significant 30-day all-cause mortality. Further research is needed regarding the causes and contributors to mortality in this population to identify patients at high risk and develop mitigation strategies.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"252 ","pages":"Article 109352"},"PeriodicalIF":3.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144166924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of new 2023 ACR/EULAR antiphospholipid syndrome classification criteria in young patients admitted for pulmonary embolism","authors":"Dalil Bouzid ,&nbsp;Diane Rouzaud ,&nbsp;Julien Rio ,&nbsp;Raphael Borie ,&nbsp;Christophe Choquet ,&nbsp;Gregory Ducrocq ,&nbsp;Jean-Francois Alexandra ,&nbsp;Antoine Dossier ,&nbsp;Thomas Papo ,&nbsp;Arthur Mageau ,&nbsp;Karim Sacre","doi":"10.1016/j.thromres.2025.109359","DOIUrl":"10.1016/j.thromres.2025.109359","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"252 ","pages":"Article 109359"},"PeriodicalIF":3.7,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the role of inflammation and proinflammatory proteins in coagulopathy during venovenous extracorporeal membrane oxygenation","authors":"Ya Wang ,&nbsp;Huadong Sun ,&nbsp;Jie Zhang ,&nbsp;Xiaowen Xie ,&nbsp;Yuheng Yu ,&nbsp;Zhenting Liang ,&nbsp;Weiyan Ye ,&nbsp;Zitao Zeng ,&nbsp;Xinyi Luo ,&nbsp;Dongdong Liu ,&nbsp;Yin Xi ,&nbsp;Rong Zhang ,&nbsp;Chun Yang ,&nbsp;Liang Zhou ,&nbsp;Manshu Li ,&nbsp;Jieyi Pan ,&nbsp;Zhiheng Xu ,&nbsp;Ling Sang ,&nbsp;Yuanda Xu ,&nbsp;Weiqun He ,&nbsp;Yonghao Xu","doi":"10.1016/j.thromres.2025.109358","DOIUrl":"10.1016/j.thromres.2025.109358","url":null,"abstract":"<div><h3>Background</h3><div>Coagulopathy frequently complicates venovenous extracorporeal membrane oxygenation (VV ECMO) procedures, yet its underlying mechanism remains elusive. This retrospective study aimed to identify factors contributing to coagulopathy during VV ECMO by analyzing clinical data and employing proteomic approaches. A prospective cohort was also examined for validation.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed clinical data from 51 patients undergoing VV ECMO between January 2015 and April 2021, categorizing them into coagulopathy(<em>n</em> = 21), defined by elevated levels of D-dimer and decreased fibrinogen in plasma that were reversible by circuit exchange, and non-coagulopathy(<em>n</em> = 30) groups. Plasma samples collected on days 0–2(D1), days 3–5(D4), and days 6–8(D7) were subjected to proteomics and Luminex assay. Additionally, oxygenator fiber samples were collected from a prospective cohort between May 2022 and August 2022 for scanning electron microscopy.</div></div><div><h3>Results</h3><div>Inflammation emerged as a pivotal factor in coagulopathy development during VV ECMO, as evidenced by elevated interleukin-6 levels on D1 and increased leukocyte and neutrophil counts on D4. Proteomics analysis identified a significant elevation of S100A8 and S100A9 in the plasma of coagulopathy patients throughout VV ECMO, findings confirmed by Luminex assay. In the prospective cohort, thrombosis and leukocyte accumulation were observed on oxygenator fibers from coagulopathy patients, along with elevated levels of S100A8 and S100A9 in plasma.</div></div><div><h3>Conclusions</h3><div>Coagulopathy during VV ECMO is associated with heightened levels of proinflammatory proteins S100A8 and S100A9 in plasma, accompanied by leukocyte accumulation on oxygenator fibers. These findings emphasize the potential therapeutic target against coagulopathy during VV ECMO.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"251 ","pages":"Article 109358"},"PeriodicalIF":3.7,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144155014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selected cell receptor genotypes differentially modulate the ABO blood group influence on Factor VIII levels in severe aortic stenosis","authors":"Barbara Lunghi ,&nbsp;Annalisa Castagna ,&nbsp;Alessio Branchini ,&nbsp;Marcello Baroni ,&nbsp;Giovanna Marchetti ,&nbsp;Gianni Mazzoni ,&nbsp;Cristina Legnani ,&nbsp;Marianna Spizzo ,&nbsp;Gabriele Mango ,&nbsp;Simonetta Friso ,&nbsp;Nicola Martinelli ,&nbsp;Francesco Bernardi","doi":"10.1016/j.thromres.2025.109356","DOIUrl":"10.1016/j.thromres.2025.109356","url":null,"abstract":"<div><h3>Background</h3><div>Altered blood flow, which characterizes aortic stenosis (AS), influences von Willebrand factor (VWF) conformation and enhances ADAMTS13 cleavage, potentially influencing factor VIII (FVIII) clearance and plasma levels.</div></div><div><h3>Aim</h3><div>To investigate whether ABO blood group and genetic variants of cellular receptors involved in VWF/FVIII clearance may interact with AS in determining genotype-driven FVIII levels.</div></div><div><h3>Patients/Methods</h3><div>FVIII:c levels were analyzed in patients with severe AS (SAS, <em>n</em> = 115), with coronary artery disease and without valvular heart disease (CAD, <em>n</em> = 300), and healthy subjects (HS, <em>n</em> = 172), clustered according to ABO and receptor genotypes. Variants with functional association with receptor mRNA and/or FVIII levels, localized in 5 receptors (<em>LDLR, STAB2, SCARA5, ASGR2, CLEC4M</em>) with different VWF/FVIII binding properties, were selected.</div></div><div><h3>Results</h3><div>In SAS group, a significant interaction between ABO and receptor genotypes in modulating FVIII:c levels was observed with positive B values for lectins (<em>ASGR2</em> and <em>CLEC4M</em>) and negative for <em>LDLR</em> and <em>STAB2</em>. The lectin variants, as well as their combinations, showed significantly lower FVIII levels in the non-O group with high glycan expression and potentially improved FVIII binding and increased clearance. Differently, the non-lectin <em>LDLR</em> and <em>STAB2</em> variants, and their combinations, were associated with genotype-driven high FVIII levels, particularly in the O group. All these patterns were not observed in CAD or HS groups.</div></div><div><h3>Conclusion</h3><div>These observations suggest that differential interaction between genotypes of specific cellular receptors and ABO blood group may contribute to high/low FVIII:c levels in O/non-O blood group subjects, respectively, and to the large inter-individual variability of FVIII levels in SAS.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"251 ","pages":"Article 109356"},"PeriodicalIF":3.7,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of mechanical pulmonary thrombectomy for intermediate-risk pulmonary embolism: Results from a prospective multicenter, multi-ethnic Asian registry","authors":"Ting Wei Teo ,&nbsp;Sarah Ming Li Tan ,&nbsp;Yun Yun Chiang ,&nbsp;Jhing Ruong Oh ,&nbsp;Siew Pang Chan ,&nbsp;Ivandito Kuntjoro ,&nbsp;Ting-Ting Low ,&nbsp;Peter Chang ,&nbsp;Jimmy Heng Ann Ong ,&nbsp;Poay Huan Loh ,&nbsp;Hui Wen Sim ,&nbsp;Andie Hartanto Djohan ,&nbsp;Robin Cherian ,&nbsp;Eng Soo Yap ,&nbsp;Yen Lin Chee ,&nbsp;Pipin Kojodjojo ,&nbsp;Yinghao Lim","doi":"10.1016/j.thromres.2025.109357","DOIUrl":"10.1016/j.thromres.2025.109357","url":null,"abstract":"<div><h3>Background</h3><div>Patients with intermediate-risk pulmonary embolism (PE) have significant risk of hemodynamic decompensation. Mechanical pulmonary thrombectomy (MT) allows for rapid reperfusion with reduced bleeding risks compared to systemic thrombolysis. However, data comparing efficacy and safety of MT versus anticoagulation therapy (AC) alone for intermediate-risk PE has been lacking. The aim of this study was to compare clinical outcomes of additive MT versus AC alone in intermediate-risk PE.</div></div><div><h3>Methods</h3><div>Consecutive patients with acute intermediate-risk PE were recruited and managed according to the same protocol in six hospitals. Patients undergoing MT in addition to AC were compared to a historical cohort managed with AC alone before MT was available. Primary endpoint was all-cause mortality at 30-days, while secondary endpoints were length of stay (LOS), major bleeding and hemodynamic changes.</div></div><div><h3>Results</h3><div>A total of 270 patients (50 % male, mean age 61.6 ± 16.2-years) were enrolled, of which 94 underwent MT and 176 received only AC. Immediate improvements in hemodynamics were seen after MT, comprising significantly reduced pulmonary arterial pressures (PASP) and RV/LV ratio, and increased tricuspid annular plane systolic excursion (TAPSE) and TAPSE/PASP ratio. MT patients had shorter total (5.5 [3–12.3] vs. 11 [7–23.5] days, <em>p</em> &lt; 0.001) and intensive care unit LOS (2 [1, 2] vs. 4 [2–12] days, <em>p</em> &lt; 0.001) compared to those receiving AC. MT patients had significantly lower odds of 30-days mortality (aOR 0.11, CI 0.012–0.91, <em>p</em> = 0.041). One MT patient experienced major procedural-related bleeding (1.1 %).</div></div><div><h3>Conclusion</h3><div>MT rapidly improved hemodynamics, shortened hospitalisation and lowered 30-day all-cause mortality in intermediate-risk PE with an excellent safety profile.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"251 ","pages":"Article 109357"},"PeriodicalIF":3.7,"publicationDate":"2025-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An audit of postpartum thromboprophylaxis practices and outcomes following caesarean delivery","authors":"C. Simard ,&nbsp;R. Cantara ,&nbsp;M.P. Bastrash ,&nbsp;C. Antinora ,&nbsp;M. Plourde ,&nbsp;M.J. Trahan ,&nbsp;A. Do ,&nbsp;M. Koolian ,&nbsp;E. Suarthana ,&nbsp;K. Wou ,&nbsp;I. Malhamé","doi":"10.1016/j.thromres.2025.109353","DOIUrl":"10.1016/j.thromres.2025.109353","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"251 ","pages":"Article 109353"},"PeriodicalIF":3.7,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “SSA-sMLP: A venous thromboembolism risk prediction model using separable self-attention and spatial-shift multilayer perceptrons” [Thromb. Res. volume 250 (2025) 109334]","authors":"An Gong ,&nbsp;Xintong Wei ,&nbsp;Yong Liu ,&nbsp;Zhenzhen Chen ,&nbsp;Bitian Fan ,&nbsp;Anxuan Jia ,&nbsp;Shuhui Wu","doi":"10.1016/j.thromres.2025.109350","DOIUrl":"10.1016/j.thromres.2025.109350","url":null,"abstract":"","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"251 ","pages":"Article 109350"},"PeriodicalIF":3.7,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144071466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coagulopathy in Dabie bandavirus infection is related to endogenous heparinoids release and mast cells activation","authors":"Bin Wang ,&nbsp;Huan Bai ,&nbsp;Peihong Yuan ,&nbsp;Dengju Li ,&nbsp;Ning Tang","doi":"10.1016/j.thromres.2025.109351","DOIUrl":"10.1016/j.thromres.2025.109351","url":null,"abstract":"<div><h3>Background</h3><div>The prolonged activated partial thromboplastin time (APTT) and thrombin time in patients infected with <em>Dabie bandavirus</em> (DBV) have been recognized to be poor prognostic indicators and attributed to a heparin-like effect rather than a decrease in coagulation factor levels.</div></div><div><h3>Objectives</h3><div>To clarify the correlation between endogenous heparinoids and coagulopathy in patients infected with DBV, and their possible sources.</div></div><div><h3>Methods</h3><div>One hundred and twenty-one consecutive patients with confirmed DBV infection were enrolled in this prospective, single-center, observational study. Routine coagulation parameters, levels of syndecan-1, heparan sulphate (HS) and mast cell tryptase (MCT), and thrombin generation (TG) profile of these patients on admission were detected, and their outcomes were recorded.</div></div><div><h3>Results</h3><div>In the enrolled patients, prolonged APTT was associated with lower TG and higher levels of syndecan-1, HS and MCT (<em>P</em> &lt; 0.05). There was a strong correlation between HS and MCT (<em>r</em> = 0.879, <em>P</em> &lt; 0.001) and a weak correlation between HS and syndecan-1 (<em>r</em> = 0.252, <em>P</em> = 0.006). With the increase of viral load, both of the MCT and HS levels were significantly elevated, and levels of endogenous thrombin potential (ETP) was significantly decreased (<em>P</em> &lt; 0.05). Age, ETP and MCT were independent predictors for 28-day mortality of patients infected with DBV (<em>P</em> &lt; 0.05).</div></div><div><h3>Conclusions</h3><div>The coagulopathy in SFTS patients were related to decreased TG, endogenous heparinoids release and mast cells activation caused by DBV infection. Further study is needed to confirm whether blocking mast cells activation has the potential to improve their coagulopathy and prognosis.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"251 ","pages":"Article 109351"},"PeriodicalIF":3.7,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144083683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro effects of Mim8 and combined Mim8-bypassing therapy on thrombin generation, thromboelastography and fibrin clot ultrastructure","authors":"Hamdi Rezigue ,&nbsp;Laurie Josset ,&nbsp;Christophe Nougier ,&nbsp;Jacob Lund ,&nbsp;G. Yesim Dargaud","doi":"10.1016/j.thromres.2025.109341","DOIUrl":"10.1016/j.thromres.2025.109341","url":null,"abstract":"<div><h3>Introduction</h3><div>Mim8, a fully human bispecific IgG4 antibody, FVIIIa mimetic, which emerges as a promising prophylactic treatment option for patients with hemophilia A (HA).</div></div><div><h3>Aim</h3><div>This study investigates the in vitro hemostatic activity of Mim8 in blood samples from six patients with severe hemophilia A using a thrombin generation assay (TGA) and thromboelastography. The results were compared to those obtained with emicizumab.</div></div><div><h3>Materials and methods</h3><div>TG was assessed in both platelet-poor (PPP) and platelet-rich plasma (PRP). Fibrin clots formed during TG were collected, and clot ultrastructure was examined using scanning electron microscopy (SEM). Whole blood samples were analyzed using ROTEM-NATEM.</div></div><div><h3>Results</h3><div>Mim8 significantly improved the TG capacity of severe HA plasma samples. Mim8 6 μg/mL demonstrated higher TG capacity compared to emicizumab 50 μg/mL. In PRP samples fortified with Mim8 6 μg/mL and rFVIIa 90 μg/kg together, ETP levels were fully normalized. No synergistic effect was observed when FVIII concentrate was combined with Mim8 at therapeutic doses due to the higher affinity of FVIII for FIXa and FX compared to Mim8. ROTEM-NATEM in whole blood confirmed the TGA results. SEM showed a more robust fibrin clot structure with thinner fibrin fibers in the presence of Mim8 compared to emicizumab.</div></div><div><h3>Conclusions</h3><div>Mim8 significantly improves TG in vitro in both PPP and PRP from patients with severe HA, with ETP levels comparable to those of FVIII at 100 IU/dL. The TGA can effectively monitor the combined treatment with Mim8 and either rFVIIa or APCC, which is not possible with currently available routine laboratory tests.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"251 ","pages":"Article 109341"},"PeriodicalIF":3.7,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends of hospital admissions due to acute limb ischemia and venous thromboembolism in Austria: A population-wide observational analysis from 2009 to 2023","authors":"Maria Elisabeth Leinweber,&nbsp;Fadi Taher,&nbsp;Afshin Assadian,&nbsp;Amun Hofmann","doi":"10.1016/j.thromres.2025.109337","DOIUrl":"10.1016/j.thromres.2025.109337","url":null,"abstract":"<div><h3>Objective</h3><div>Thrombosis-related conditions account for approximately 25 % of global mortality, underlying major vascular emergencies such as acute limb ischemia (ALI) and venous thromboembolism (VTE). However, real-world data on long-term epidemiological trends remain limited. The present study aimed at investigating trends in the epidemiology of acute limb ischemia (ALI), pulmonary embolism (PE), and deep venous thrombosis (DVT).</div></div><div><h3>Methods</h3><div>This retrospective population-based study analyzed hospital-admitted ALI and VTE in Austria between 2009 and 2023 using a federal inpatient database. Analyses included annual incidence and incidence rates, in-hospital mortality, comorbidities, major complications, and demographic characteristics for ALI, PE, and DVT cases.</div></div><div><h3>Results</h3><div>Between 2009 and 2023 the Austrian population increased from 8.3 mio to 9.1 mio. Inhabitants, with the proportion of individuals of &gt;65 years of age increasing from 17.4 % to 19.6 %. The incidence rate of ALI significantly declined from 27.2 per 100,000 to 13.6 per 100,000 over the study period (−50.0 %). The proportion of female ALI patients decreased over time, while the age distribution remained unchanged. The incidence of hospital-admitted VTE also declined, particularly for DVT, which saw a 73.9 % reduction. Hospital-admitted PE incidence decreased from 89.1 per 100.000 to 73.4 per 100.000 (−17.6 %), with in-hospital mortality declining from 8.9 % to 4.2 %. The duration of hospital stay decreased for both ALI and VTE, with most patients being discharged within nine days.</div></div><div><h3>Conclusions</h3><div>A substantial decline in the incidence of hospital-admitted ALI and VTE has been observed in Austria over the past 15 years, which may be consistent with improved cardiovascular risk management, encompassing the widespread adoption of DOACs and statins, a decline in daily smoking, increased outpatient management, and advancements in perioperative thromboprophylaxis.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"251 ","pages":"Article 109337"},"PeriodicalIF":3.7,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143942395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}